Rhys Whomsley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rhys Whomsley has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- A. Londenberg
Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Hannover, Germany
1 shared publication A. Y. J. Dahneem
Welsh School of Pharmacy, University of Wales College of Cardiff, PO Box 13, Cardiff, S Glam, UK
1 shared publicationAisar Atrakchi
US Food and Drug Administration/Center for Drug Evaluation and Research , Silver Spring, MD 20993
1 shared publication- Alisa Vespa
Pharmaceutical Drugs Directorate, Health Canada , Ottawa, ON, K1A 0K9
1 shared publication Ana Hidalgo‐Simon
Head of Advanced Therapies, Human Medicines Division European Medicines Agency (EMA) Amsterdam The Netherlands
1 shared publication- Andreas Czich
Sanofi, R&D Translational Medicine Preclinical Safety , Frankfurt D-69526
1 shared publication
Latest Publications
- Open Access
- 2 June 2026
- Published by Springer Nature in Archives of Toxicology
- Vol. 100 (10) , 4717-4736
The in vitro alkaline comet assay with liver models as a complementary tool for genotoxicity assessment of N-nitrosamines
N -nitrosamine (NA) impurities in pharmaceuticals represent “cohort of concern” compounds under ICH M7(R2), due to their mutagenic/carcinogenic potential, involving cytochrome P450 (CYP)-mediated metabolic activation. Increasing interest in mammalian cell-based genotoxicity/mutagenicity assays prompted our assessment of the in vitro alkaline comet assay regarding its predictive power for NAs. Here, precision-cut liver slices (PCLiS), primary human hepatocytes (PHH), primary rat hepatocytes (PRH), and HepG2 cells with rat or hamster S9-mix were investigated as in vitro model systems. Metabolic competence was characterized beforehand. For performance evaluation, a panel of known-mutagenic [ N -nitroso-dimethylamine (NDMA), N -nitroso-diethanolamine, N -nitroso-methylaniline, S – N -nitroso-nornicotine, N-methyl-N-nitroso-2-propanamine] and reported non-mutagenic (methyl-t-butylnitrosamine, N -nitrosoproline) was tested, together with Nitrosamine Drug Substance-Related Impurities [ N -nitrosodesloratadine, N -nitrosofolic acid, N -nitrosofluoxetine (NFluo)] at a concentration range of 0.005–10 mM. After 2 h (PCLiS, PHH and PRH) or 4 h (HepG2), NDMA concentration-dependently induced DNA strand breaks in all in vitro models. Sensitivity/specificity of the various liver cell models for prediction of carcinogenic NAs were 100%/50% (HepG2 with hamster S9-mix), 50%/100% (PHH, PRH), and 50%/50% (HepG2 with rat S9-mix), respectively. Benchmark dose modeling indicated a higher relative in vitro comet assay response for NFluo compared to NDMA in all cell systems. In conclusion, the in vitro comet assay represents a sensitive and/or specific tool for complementing regulatory in vitro tests in prediction of mutagenic NAs. However, further optimization work is needed, using expanded training sets of compounds and thorough validation of liver cell models, before the in vitro comet assay could be incorporated in the standard battery for genotoxicity testing.
- 2 June 2026
- Published by Springer Nature in Archives of Toxicology
- Vol. 100 (10) , 4717-4736
Open AccessThe in vitro alkaline comet assay with liver models as a complementary tool for genotoxicity assessment of N-nitrosamines
N -nitrosamine (NA) impurities in pharmaceuticals represent “cohort of concern” compounds under ICH M7(R2), due to their mutagenic/carcinogenic potential, involving cytochrome P450 (CYP)-mediated metabolic activation. Increasing interest in mammalian cell-based genotoxicity/mutagenicity assays prompted our assessment of the in vitro alkaline comet assay regarding its predictive power for NAs. Here, precision-cut liver slices (PCLiS), primary human hepatocytes (PHH), primary rat hepatocytes (PRH), and HepG2 cells with rat or hamster S9-mix were investigated as in vitro model systems. Metabolic competence was characterized beforehand. For performance evaluation, a panel of known-mutagenic [ N -nitroso-dimethylamine (NDMA), N -nitroso-diethanolamine, N -nitroso-methylaniline, S – N -nitroso-nornicotine, N-methyl-N-nitroso-2-propanamine] and reported non-mutagenic (methyl-t-butylnitrosamine, N -nitrosoproline) was tested, together with Nitrosamine Drug Substance-Related Impurities [ N -nitrosodesloratadine, N -nitrosofolic acid, N -nitrosofluoxetine (NFluo)] at a concentration range of 0.005–10 mM. After 2 h (PCLiS, PHH and PRH) or 4 h (HepG2), NDMA concentration-dependently induced DNA strand breaks in all in vitro models. Sensitivity/specificity of the various liver cell models for prediction of carcinogenic NAs were 100%/50% (HepG2 with hamster S9-mix), 50%/100% (PHH, PRH), and 50%/50% (HepG2 with rat S9-mix), respectively. Benchmark dose modeling indicated a higher relative in vitro comet assay response for NFluo compared to NDMA in all cell systems. In conclusion, the in vitro comet assay represents a sensitive and/or specific tool for complementing regulatory in vitro tests in prediction of mutagenic NAs. However, further optimization work is needed, using expanded training sets of compounds and thorough validation of liver cell models, before the in vitro comet assay could be incorporated in the standard battery for genotoxicity testing.
- Open Access
- 14 February 2026
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 41 (4) , 225-236
Nitrosamine Ames Data Review and Method Development: proceedings of a US FDA/HESI workshop
Detection of N-nitrosamines (NA) in pharmaceuticals became a point of interest due to the mutagenic and carcinogenic potential of some compounds of this class, and their identification as nitrosated forms of marketed drugs, otherwise known as NA Drug Substance-Related Impurities (NDSRIs). The Ames test is used to assess the mutagenic potential of drug impurities, including NAs. Concerns over the sensitivity of the Ames test, as recommended in Organization for Economic Co-operation and Development Test Guideline 471, in predicting the rodent carcinogenic potential of NAs has prompted optimization of several test parameters used for detecting the mutagenicity of NAs (e.g. methods used for metabolic activation and the selection of tester strains). In order to discuss optimal Ames test conditions for the evaluation of NAs, including NDSRIs, the Office of New Drugs in the US Food and Drug Administration’s Center for Drug Evaluation and Research and the Health and Environmental Sciences Institute’s Genetic Toxicology Technical Committee co-organized and co-sponsored a workshop entitled “Nitrosamines: Ames Data Review and Method Development Workshop”. The workshop featured five sessions addressing charge questions pertinent to the Ames test conditions and performance through the presentation of data and panel discussions. This report outlines the key takeaway points from the workshop.
- 14 February 2026
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 41 (4) , 225-236
Open AccessNitrosamine Ames Data Review and Method Development: proceedings of a US FDA/HESI workshop
Detection of N-nitrosamines (NA) in pharmaceuticals became a point of interest due to the mutagenic and carcinogenic potential of some compounds of this class, and their identification as nitrosated forms of marketed drugs, otherwise known as NA Drug Substance-Related Impurities (NDSRIs). The Ames test is used to assess the mutagenic potential of drug impurities, including NAs. Concerns over the sensitivity of the Ames test, as recommended in Organization for Economic Co-operation and Development Test Guideline 471, in predicting the rodent carcinogenic potential of NAs has prompted optimization of several test parameters used for detecting the mutagenicity of NAs (e.g. methods used for metabolic activation and the selection of tester strains). In order to discuss optimal Ames test conditions for the evaluation of NAs, including NDSRIs, the Office of New Drugs in the US Food and Drug Administration’s Center for Drug Evaluation and Research and the Health and Environmental Sciences Institute’s Genetic Toxicology Technical Committee co-organized and co-sponsored a workshop entitled “Nitrosamines: Ames Data Review and Method Development Workshop”. The workshop featured five sessions addressing charge questions pertinent to the Ames test conditions and performance through the presentation of data and panel discussions. This report outlines the key takeaway points from the workshop.
- Open Access
- 2 June 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (8) , 2341-2348
EMA commentary on the ICH guideline for testing for carcinogenicity of pharmaceuticals
- 2 June 2023
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (8) , 2341-2348
Open AccessEMA commentary on the ICH guideline for testing for carcinogenicity of pharmaceuticals
- Open Access
- 18 February 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (6) , 2450-2458
Environmental risk assessment of advanced therapies containing genetically modified organisms in the EU
Gene therapy medicinal products have the potential to provide curative treatment for many diseases with current limited therapeutic options. As advanced therapy medicinal products (ATMPs), these therapies undergo a centralised, single European Union authorisation by the European Medicines Agency (EMA), but the risks, and potential harm to the environment and population at large are weighted in each application, and different interpretations at national level exist. A streamlined procedure is now in place to facilitate a consistent approach for the assessment of the environmental risks of medicines containing genetically modified organisms for both clinical trial applications and marketing authorisation applications. This article provides an overview of basic requirements across the EU, an overview of the new streamlined process and discusses available guidance for developers with particular emphasis on marketing authorisation applications. All these initiatives are aimed to remove hurdles for ATMP developers and facilitate faster access to patients.
- 18 February 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (6) , 2450-2458
Open AccessEnvironmental risk assessment of advanced therapies containing genetically modified organisms in the EU
Gene therapy medicinal products have the potential to provide curative treatment for many diseases with current limited therapeutic options. As advanced therapy medicinal products (ATMPs), these therapies undergo a centralised, single European Union authorisation by the European Medicines Agency (EMA), but the risks, and potential harm to the environment and population at large are weighted in each application, and different interpretations at national level exist. A streamlined procedure is now in place to facilitate a consistent approach for the assessment of the environmental risks of medicines containing genetically modified organisms for both clinical trial applications and marketing authorisation applications. This article provides an overview of basic requirements across the EU, an overview of the new streamlined process and discusses available guidance for developers with particular emphasis on marketing authorisation applications. All these initiatives are aimed to remove hurdles for ATMP developers and facilitate faster access to patients.
- Open Access
- 11 March 2019
- Published by Springer Nature in Environmental Sciences Europe
- Vol. 31 (1) , 17
Commentary on the draft revised guideline on the environmental risk assessment of medicinal products for human use
- 11 March 2019
- Published by Springer Nature in Environmental Sciences Europe
- Vol. 31 (1) , 17
Open AccessCommentary on the draft revised guideline on the environmental risk assessment of medicinal products for human use
- 15 July 2009
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 41 (3) , 422-454
Pharmacokinetics in special populations
Pharmacokinetics are typically dependent on a variety of physiological variables (e.g., age, ethnicity, or pregnancy) or pathological conditions (e.g., renal and hepatic insufficiency, cardiac dysfunction, obesity, etc.). The influence of some of these conditions has not always been thoroughly assessed in the clinical studies of antiallergic drugs. However, the knowledge of the physiological grounds of the pharmacokinetics can provide some insight for predicting the potential alterations and guiding the initial prescription strategies. It is important to recognize that both pharmacokinetic and pharmacodynamic differences between populations should be considered. The available information on drugs used for the therapy of allergic diseases is reviewed in this chapter.
- 15 July 2009
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 41 (3) , 422-454
Pharmacokinetics in special populations
Pharmacokinetics are typically dependent on a variety of physiological variables (e.g., age, ethnicity, or pregnancy) or pathological conditions (e.g., renal and hepatic insufficiency, cardiac dysfunction, obesity, etc.). The influence of some of these conditions has not always been thoroughly assessed in the clinical studies of antiallergic drugs. However, the knowledge of the physiological grounds of the pharmacokinetics can provide some insight for predicting the potential alterations and guiding the initial prescription strategies. It is important to recognize that both pharmacokinetic and pharmacodynamic differences between populations should be considered. The available information on drugs used for the therapy of allergic diseases is reviewed in this chapter.
- 1 January 1993
- Published by Taylor & Francis in Journal of Enzyme Inhibition
- Vol. 7 (2) , 137-145
1-Pentyl-3-(4-Aminophenyl)Pyrrolidine-2, 5-Dione, A Selective Aromatase Inhibitor:in vivoStudies
1-Pentyl, 1-hexyl and 1-heptyl-3-(4-aminophenyl)pyrrolidine-2,5-dione, potent inhibitors of aromatase, lower oestrogen levels in PMSG-stimulated female rats in a comparable manner to the inhibitor aminoglutethimide (AG) used clinically for the treatment of breast cancer. Pharmacokinetic studies in the rat show t 1/2 values for the 1-hexyl compound and AG of 1.8 and 5.5 h respectively. In 4 tests for CNS-depressant activity the overall order of activity was AG > 1-heptyl = 1- hexyl > 1-pentyl. The 1-pentyl compound has less tendency than AG to depress white cell and platelet counts in mice and overall is the drug candidate for further studies.
- 1 January 1993
- Published by Taylor & Francis in Journal of Enzyme Inhibition
- Vol. 7 (2) , 137-145
1-Pentyl-3-(4-Aminophenyl)Pyrrolidine-2, 5-Dione, A Selective Aromatase Inhibitor:in vivoStudies
1-Pentyl, 1-hexyl and 1-heptyl-3-(4-aminophenyl)pyrrolidine-2,5-dione, potent inhibitors of aromatase, lower oestrogen levels in PMSG-stimulated female rats in a comparable manner to the inhibitor aminoglutethimide (AG) used clinically for the treatment of breast cancer. Pharmacokinetic studies in the rat show t 1/2 values for the 1-hexyl compound and AG of 1.8 and 5.5 h respectively. In 4 tests for CNS-depressant activity the overall order of activity was AG > 1-heptyl = 1- hexyl > 1-pentyl. The 1-pentyl compound has less tendency than AG to depress white cell and platelet counts in mice and overall is the drug candidate for further studies.